Tamsulosin Hydrochloride
FDA-approved product (capsule, oral), marketed as Flomax, Tamsulosin Hydrochloride.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Benign prostatic hyperplasia
- Prostate carcinoma
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Alpha-adrenoreceptor antagonists
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA28.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli31.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae21.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis73.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Tamsulosin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- PlecanatideExisting use: Constipation52.2% AI-predicted activityagainst K. pneumoniae15 registered studies
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma51.3% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome50.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Terlipressin AcetateExisting use: Hepatorenal syndrome, Kidney failure, Renal insufficiency49.5% AI-predicted activityagainst K. pneumoniae7 registered studies
- LetermovirExisting use: Cytomegalovirus infection, Infection, Viral disease49.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Codeine SulfateExisting use: Cough, Drug dependence, Migraine disorder and 2 more48.8% AI-predicted activityagainst K. pneumoniae23 registered studies
- Bromocriptine MesylateExisting use: Acromegaly, Adenoma, Hyperprolactinemia and 4 more48.5% AI-predicted activityagainst K. pneumoniae50+ registered studies
- PimecrolimusExisting use: Atopic eczema, Eczematoid dermatitis48.3% AI-predicted activityagainst K. pneumoniae50+ registered studies
- LypressinExisting use: Vasopressin and analogues48.2% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Degarelix AcetateExisting use: Prostate adenocarcinoma, Prostate cancer, Prostate carcinoma48.2% AI-predicted activityagainst K. pneumoniae50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more48.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Dolutegravir SodiumExisting use: HIV infection, HIV-1 infection47.9% AI-predicted activityagainst K. pneumoniae50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Effect of Preoperative Alpha-blockers on Successful Insertion Ureteral Access Sheath and Reduce Ureteral Injury in Non-prestented Patients During RIRS. Assessment of Factors for Successful Ureteral Access Sheath Insertion.
NCT07202923 · start 2021-07-09
Registered record
- Registry ID
- NCT07202923
- Conditions
- Urolithiasis; Ureteral Injury; Ureteral Access Sheath; Retrograde Intrarenal Surgery
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2021-07-09
- Completion
- 2024-06-02
- Enrolment
- 140
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionUrolithiasis; Ureteral Injury; Ureteral Access Sheath; Retrograde Intrarenal SurgeryInterventionNot recordedPhaseNot recordedRegistry statusCompletedEfficacy of Antihistamine Drugs as Medical Expulsive Therapy Alone or in Combination With Alpha Blockers: A Prospective Randomized Controlled Study
NCT06754410 · start 2021-03-01
Registered record
- Registry ID
- NCT06754410
- Conditions
- Lower Ureteric Stones
- Interventions
- Tamsulosin; Cetirizine; Cetirizine + Tamsulosin; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2021-03-01
- Completion
- 2024-03-01
- Enrolment
- 480
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLower Ureteric StonesInterventionTamsulosin; Cetirizine; Cetirizine + Tamsulosin; PlaceboPhasePhase 3Registry statusCompletedThe Efficacy and Safety of Medical Expulsive Therapy After Extracorporeal Shock Wave Lithotripsy (ESWL) in Pediatric Urolithiasis
NCT05759767 · start 2021-02-01
Registered record
- Registry ID
- NCT05759767
- Conditions
- Tamsulosin; Extracorporeal Shock Wave Lithotripsy; Stone, Kidney; Stone, Urinary; Pediatric Disorder
- Interventions
- Tamsulosin; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2021-02-01
- Completion
- 2023-12-01
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTamsulosin; Extracorporeal Shock Wave Lithotripsy; Stone, Kidney; Stone, Urinary +1 moreInterventionTamsulosin; PlaceboPhaseNot applicableRegistry statusUnknownComparison Between Tamsulosin and Tadalafil in Management of Benign Prostatic Hyperplasia Long Term Study
NCT05818670 · start 2020-11-11
Registered record
- Registry ID
- NCT05818670
- Conditions
- BPH
- Interventions
- Tamsulosin; Tadalafil
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2020-11-11
- Completion
- 2022-09-17
- Enrolment
- 160
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBPHInterventionTamsulosin; TadalafilPhasePhase 4Registry statusCompletedHerbal Supplement Prosta-OK® Neo as an Adjunct Therapy in Patients With Mild to Severe Non-neurogenic Male Lower Urinary Tract Symptoms Receiving Tamsulosin Therapy
NCT04418635 · start 2020-06-04
Registered record
- Registry ID
- NCT04418635
- Conditions
- Lower Urinary Tract Symptoms
- Interventions
- Prosta-OK® Neo or Prosta-OK® Neo-matched placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2020-06-04
- Completion
- 2021-12-31
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLower Urinary Tract SymptomsInterventionProsta-OK® Neo or Prosta-OK® Neo-matched placeboPhaseNot applicableRegistry statusUnknownMedical Expulsive Therapy Post-SWL For Renal Stones
NCT05032287 · start 2019-09-01
Registered record
- Registry ID
- NCT05032287
- Conditions
- Urologic Diseases; Urolithiasis; Stone, Kidney
- Interventions
- Tamsulosin; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2019-09-01
- Completion
- 2020-05-01
- Enrolment
- 235
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionUrologic Diseases; Urolithiasis; Stone, KidneyInterventionTamsulosin; PlaceboPhaseNot applicableRegistry statusCompletedPre-induction Analgesia: Multimodel Regimen vs Aceteminophen for Post Ureteroscopy Pain
NCT03549611 · start 2018-08-01
Registered record
- Registry ID
- NCT03549611
- Conditions
- Kidney Calculi; Pain, Postoperative
- Interventions
- Multimodal Oral Drug Regimen; Acetaminophen
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Withdrawn
- Start
- 2018-08-01
- Completion
- 2019-06-30
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionKidney Calculi; Pain, PostoperativeInterventionMultimodal Oral Drug Regimen; AcetaminophenPhasePhase 4Registry statusWithdrawnMirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study
NCT03600766 · start 2018-08-01
Registered record
- Registry ID
- NCT03600766
- Conditions
- BPH; Erectile Dysfunction; Prostate Hyperplasia; Erectile Abnormalities; Prostatic Neoplasms
- Interventions
- Mirabegron; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2018-08-01
- Completion
- 2020-01-01
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBPH; Erectile Dysfunction; Prostate Hyperplasia; Erectile Abnormalities +1 moreInterventionMirabegron; placeboPhasePhase 2Registry statusUnknownProstatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia
NCT02869971 · start 2016-08
Registered record
- Registry ID
- NCT02869971
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Embosphere® (Prostatic Arteries Embolization); Drug therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2016-08
- Completion
- 2022-03-25
- Enrolment
- 90
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBenign Prostatic HyperplasiaInterventionEmbosphere® (Prostatic Arteries Embolization); Drug therapyPhasePhase 3Registry statusCompletedA Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
NCT02757768 · start 2016-06-13
Registered record
- Registry ID
- NCT02757768
- Conditions
- Benign Prostatic Hyperplasia; Overactive Bladder
- Interventions
- Mirabegron; Placebo; Tamsulosin Hydrochloride
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2016-06-13
- Completion
- 2018-09-11
- Enrolment
- 715
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBenign Prostatic Hyperplasia; Overactive BladderInterventionMirabegron; Placebo; Tamsulosin HydrochloridePhasePhase 4Registry statusCompletedStudy to Compare the Safety and Pharmacokinetics of CKD-397
NCT02645890 · start 2015-11
Registered record
- Registry ID
- NCT02645890
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- CKD-397; TD+TM
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2015-11
- Completion
- 2015-12
- Enrolment
- 36
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBenign Prostatic HyperplasiaInterventionCKD-397; TD+TMPhasePhase 1Registry statusCompletedThe Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil
NCT03144596 · start 2015-10-29
Registered record
- Registry ID
- NCT03144596
- Conditions
- Benign Prostatic Hyperplasia; Pupil Anomaly; Choroid Disease
- Interventions
- Alfuzosin Hydrochloride 10 MG; Tamsulosin Hydrochloride 0.4 MG
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2015-10-29
- Completion
- 2016-11-19
- Enrolment
- 63
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBenign Prostatic Hyperplasia; Pupil Anomaly; Choroid DiseaseInterventionAlfuzosin Hydrochloride 10 MG; Tamsulosin Hydrochloride 0.4 MGPhasePhase 4Registry statusCompletedDetermine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fasted Male.
NCT02417831 · start 2015-04-30
Registered record
- Registry ID
- NCT02417831
- Conditions
- Prostatic Hyperplasia
- Interventions
- tamsulosin capsules; tamsulosin HCl
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2015-04-30
- Completion
- 2015-05-31
- Enrolment
- 34
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstatic HyperplasiaInterventiontamsulosin capsules; tamsulosin HClPhasePhase 1Registry statusCompletedDetermine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fed Male.
NCT02417844 · start 2015-04
Registered record
- Registry ID
- NCT02417844
- Conditions
- Prostatic Hyperplasia
- Interventions
- tamsulosin (Astellas); Tamsulosin HCL
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2015-04
- Completion
- 2015-05
- Enrolment
- 34
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstatic HyperplasiaInterventiontamsulosin (Astellas); Tamsulosin HCLPhasePhase 1Registry statusCompletedEvaluating a Pharmacokinetic Drug Interaction Between Tadalafil and Tamsulosin
NCT02239484 · start 2014-03
Registered record
- Registry ID
- NCT02239484
- Conditions
- Erectile Dysfunction; Benign Prostatic Hyperplasia
- Interventions
- Tadalafil; Tamsulosin; Tadalafil + Tamsulosin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2014-03
- Completion
- 2014-09
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile Dysfunction; Benign Prostatic HyperplasiaInterventionTadalafil; Tamsulosin; Tadalafil + TamsulosinPhasePhase 1Registry statusCompleted